Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,498

Utilizing induced pluripotent stem cells for regenerative medicine.

The #heart is the first organ to develop in the womb and the first cause of concern for many parents.

For expecting mothers, the excitement of pregnancy is often offset by anxiety over medication they require. Parents and doctors often have to consider the mother’s health as well as the potential risk regarding how medication could affect their baby. The U.S. Food and Drug Administration requires certain drugs to be labeled with pregnancy exposure and risk. Some drugs are labeled to show that testing on animals has failed to demonstrate a risk but there are no adequate and well-controlled studies of pregnant women.

“Some drugs are difficult for doctors to prescribe to pregnant women because they don’t know the embryo toxicity, how does that effect fetal development,” said biomedical engineering Professor Zhen Ma. “They don’t have the clinical outcome based on human study.”

Read more

Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination #chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results in animal models so far suggest this approach could one day ramp up therapeutic benefits for patients bearing tumors or after removal of the primary tumors.

The research, published in Science Translational Medicine, focused on two specific types of melanoma and breast #cancer, but this approach could work in other tissue types. Also, the research showed that this localized delivery of combination therapy significantly inhibited the recurrence of cancer after the primary was surgically removed.

“We’ve created a simple method to use #chemotherapy while leveraging the biology of the #tumor and our natural defense against foreign invaders to beat back with limited side effects,” said senior author Zhen Gu, PhD, associate professor in the joint UNC/NCSU Biomedical Engineering Department. “We have a lot more work to do before human clinical trials, but we think this approach holds great promise.”

Read more

It’s not uncommon for the press to get hyped up before the long process of refinement and FDA approval. Let’s hope that this one moves along quickly — while demonstrating safety and efficacy.

https://www.troab.com/worlds-first-bionic-kidney-set-replace…-two-years

Parte 3 of the SENS Research Foundation interview by LEAF is out!

Welcome to part three and the final part of our SENS Undoing Aging 2018 interview; we have a few more scientific questions today for Aubrey and his team as well as questions about future developments and taking new therapies to market.

Dr. de Grey, has your position on the relevance of telomere attrition changed since you first devised SENS, especially in the light of the recent results with fibrosis and your involvement with AgeX?

Aubrey: No. Let’s start with the big picture. Neither I nor anyone sensible has ever suggested that telomere attrition has no functional effects in aging: telomere attrition causes cells to become senescent and runs down the proliferative capacity of stem cells, amongst other things. Nor have I suggested that there wouldn’t be some short-term health benefits to activating telomerase or telomerase gene therapy in aging animals or animal models of age-related disease (or even their human equivalents). Indeed, there was plenty of animal data to support this long before the recent results with a mouse model of idiopathic pulmonary fibrosis (IPF)[1].

Read more

Sometimes I think I’m jumping the gun when speculating. Take this further, a better full body replacement?

The more we study natural biological cells, the more we learn about how to control them or build artificial versions. These independent avenues of study have huge potential, but also their limitations. Researchers from Imperial College London have worked out a way to borrow the strengths of each, fusing together living and non-living cells to create tiny chemical factories that might one day aid drug delivery.

In past work, scientists have packaged proteins and enzymes inside artificial casings to better treat conditions like cancer or diabetes. Rather than just using some natural parts, the Imperial College study instead wrapped entire biological cells inside artificial ones.

“Biological cells can perform extremely complex functions, but can be difficult to control when trying to harness one aspect,” says Oscar Ces, lead researcher on the project. “Artificial cells can be programmed more easily but we cannot yet build in much complexity. Our new system bridges the gap between these two approaches by fusing whole biological cells with artificial ones, so that the machinery of both works in concert to produce what we need.”

Read more

“The Theranos story is an important lesson for Silicon Valley,” said Jina Choi, director of the SEC’s San Francisco Regional Office. “Innovators who seek to revolutionize and disrupt an industry must tell investors the truth about what their technology can do today, not just what they hope it might do someday.”

Elizabeth Holmes raised hundreds of millions of dollars from investors on the promise that her medical-testing startup Theranos Inc. would change medicine with a single drop of blood. On Wednesday, securities regulators called her a fraud and forced her to give up the company she built.

The lawsuit and settlement announced Wednesday by the U.Securities and Exchange Commission detailed how Holmes and her chief deputy lied for years about their technology, snookered the media, and used the publicity to get investors to hand more than $700 million to keep the closely held company afloat.

Read more

Spending an extended period of time in outer space takes a toll on the human body. And while NASA was aware of some physical changes that astronauts needed to be prepared for upon coming back to Earth, they were curious to learn further about how extended space time would affect a human body on a molecular level. After one astronaut spent a year in space, NASA was able to determine that the prolonged spaceflight actually altered his DNA.

Astronaut Scott Kelly and his twin brother Mark Kelly took part in NASA’s twin study, a means to compare the human body on Earth to its counterpart following a year in space. While Scott spent a year in space, Mark stayed behind, and upon Scott’s return, NASA was able to track and monitor the ways that spaceflight had altered Scott’s body.

via GIPHY

Read more

The difference between traditional radiation and proton therapy is in how the radiation is delivered.

Traditional therapy irradiates tumors with X-ray waves, and all tissue along the beams’ path gets a similar dose of radiation.

Proton therapy instead uses beams of protons, charged subatomic particles that can be controlled with magnets. A small amount of radiation is deposited on the way into the body, most of it goes directly into the tumor, and none passes through the other side.

Read more

The genomes of the long dead are turning up all sorts of unexpected and controversial findings.

Geneticist David Reich used to study the living, but now he studies the dead.

The precipitating event came in the form of 40,000-year-old Neanderthal bones found in a Croatian cave. So well-preserved were the bones that they yielded enough DNA for sequencing, and it became Reich’s job in 2007 to analyze the DNA for signs that Neanderthals interbred with humans—a idea he was “deeply suspicious” of at the time.

Read more